 |
Depósito mínimo $50 Promoção exclusiva |
Nossa pontuação |
0% comissão |
Are you looking to buy Incyte stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:INCY! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Incyte stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Volume médio
1,18 milhões de shms
MERCADO CAP
$20.34 billion
Bolsa de Valores
NASDAQ
Comprem essas ações!
|
NOME
|
TICKER
|
INDÚSTRIA
|
SECTOR
|
VOLUME
|
COMPRAR AGORA ESSAS AÇÕES
|
|---|---|---|---|---|---|
|
NASDAQ: INCY
|
Pesquisa física comercial
|
Médico
|
20,524 shs
|
Below is a quick guide on how to buy NASDAQ:INCY stocks safe, fast and around the world in less than five minutes.
Passo 1: Abrir uma conta no eToro – eToro is the best broker to buy Incyte shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Passo 2: Carregue sua identificação - Conforme os regulamentos da KYC, eToro lhe pedirá que carregue uma cópia de seu passaporte ou de sua carteira de motorista.
Etapa 3: Fundos de depósito - Deposite algum dinheiro em sua recém-criada conta eToro. O senhor pode escolher entre transferência bancária, carteira eletrônica, cartão de débito/crédito ou Paypal.
Passo 4: Buy Incyte – Search for “”NASDAQ:INCY”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Incyte stocks with 0% commission!.
1 | | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
21 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Incyte in the last twelve months. There are currently 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Incyte stock.
Wall Street analysts have given Incyte a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Incyte wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
2 |  | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
3 |  | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:INCY stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Incyte stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Incyte stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Como o eToro é uma plataforma regulamentada, o senhor precisará completar o processo KYC, isso é uma prática padrão e leva apenas alguns minutos. O senhor precisará fornecer um documento de identificação com foto (passaporte, carteira de motorista) e comprovante de endereço (conta de serviços públicos, extrato bancário).
Uma vez que o senhor tenha se inscrito e verificado sua conta, precisará depositar fundos. eToro aceita cartões de crédito/débito, transferências bancárias, e também carteiras eletrônicas. Portanto, qualquer que seja sua preferência, haverá algo para o senhor.
Now that you’ve funded your eToro account, just type “NASDAQ:INCY stocks” na barra de busca na parte superior da tela e pressione "trade".
All that’s left is to buy some NASDAQ:INCY stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:INCY is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Incyte stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Incyte.
Incyte will be holding an earnings conference call on Tuesday, February 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
Incyte Co. (NASDAQ:INCY) issued its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by $0.23. The biopharmaceutical company had revenue of $620.64 million for the quarter, compared to the consensus estimate of $622.48 million. Incyte had a negative net margin of 13.62% and a negative trailing twelve-month return on equity of 13.66%. Incyte’s revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.82 EPS.
View Incyte’s earnings history.
Incyte’s stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 28.5% and is now trading at $92.42.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:INCY stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Mais de 95% de fundos de clientes são mantidos offline, em câmara fria, o que é crucial para qualquer corretor que administre seus ativos. Independentemente de quão segura deve ser uma plataforma, recomendamos o uso do 2FA para acrescentar uma camada adicional de segurança à sua conta.
eToro oferece aos usuários uma gama de recursos para começar a investir o mais rapidamente possível. Eles têm uma característica relativamente única chamada negociação de cópias, que lhe permite ganhar uma renda passiva ao espelhar comerciantes experientes, o que lhe permite começar a ter lucro rapidamente, e lhe dá uma melhor compreensão das estratégias usadas pelos profissionais. Além disso, o eToro permite aos usuários investir em carteiras administradas, sendo uma carteira administrada uma variedade de ativos semelhantes agrupados, permitindo ao senhor diversificar sua conta, reduzindo qualquer risco potencial. Para aqueles com experiência anterior em negociação, o senhor pode investir em mercados fora das ações, já que eToro permite aos usuários negociar ETFs, commodities, criptografia e índices. Se o senhor já investir fora do espaço da bolsa de valores, isso pode ser muito útil, pois permite ao senhor administrar todos os seus investimentos em um só lugar.
21 brokers have issued twelve-month price targets for Incyte’s shares. Their forecasts range from $86.00 to $124.00. On average, they anticipate Incyte’s share price to reach $103.56 in the next year. This suggests a possible upside of 12.1% from the stock’s current price.
View analysts’ price targets for Incyte or view top-rated stocks among Wall Street analysts.
Incyte’s management team includes the following people:
Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 61, Pay $2.47M)
Ms. Christiana Stamoulis, Exec. VP & CFO (Age 50, Pay $1.2M)
Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 58, Pay $847.81k)
Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA, Exec. VP & GM of North America (Age 63, Pay $803.14k)
Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 54, Pay $937.73k)
Mr. Michael James Morrissey, Exec. VP & Head of Global Technical Operations (Age 57)
Dr. Dashyant Dhanak Ph.D., Exec. VP & Chief Scientific Officer (Age 60)
Mr. Michael Booth DPhil, Divisional VP of Investor Relations & Corp. Social Responsibility (Age 50)
Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel (Age 55)
Ms. Pamela M. Murphy, VP of Investor Relations & Corp. Communications (Age 70)
Os CFDs são instrumentos complexos e vêm com um alto risco de perder dinheiro rapidamente devido à alavancagem. 68% de contas de investidores de varejo perdem dinheiro ao negociar CFDs com esse provedor. O senhor deve considerar se compreende como os CFDs funcionam, e se pode arcar com o alto risco de perder seu dinheiro.
22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte’s employees.
Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
View all of INCY’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).
Incyte trades on the NASDAQ under the ticker symbol “INCY.”
1 | | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
Incyte’s stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.13%), California Public Employees Retirement System (0.69%), First Trust Advisors LP (0.41%), Sumitomo Mitsui Trust Holdings Inc. (0.39%), Swiss National Bank (0.32%) and Candriam Luxembourg S.C.A. (0.26%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.
INCY stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Frontier Capital Management Co. LLC, Shikiar Asset Management Inc., Nissay Asset Management Corp Japan ADV, Robeco Institutional Asset Management B.V., NorthCoast Asset Management LLC, California Public Employees Retirement System, and Comerica Bank. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte or view top insider-selling stocks.
INCY stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., SG Americas Securities LLC, US Bancorp DE, Nippon Life Global Investors Americas Inc., QCI Asset Management Inc. NY, and Retirement Systems of Alabama.
View insider buying and selling activity for Incyte or or view top insider-buying stocks.
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Revisão dos Corretores Interativos, Revisão eToro, Revisão DEGiro, Revisão da AvaTrade, IG Markets Review, Revisão dos Mercados de IC, CMC Markets Review, Admiral Markets Review e muitos mais. Leia uma das revisões para saber tudo sobre o corretor e comece agora a comprar ações.
One share of INCY stock can currently be purchased for approximately $92.42.
Incyte has a market capitalization of $20.24 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis.
No Reportlab.org queremos garantir que o senhor tenha todas as informações mais relevantes sobre compra de ações. Trazemos-lhe os melhores guias sobre o mercado de ações, com revisões pessoais, informações de base, revisões de plataforma, como fazer e muito mais. Deseja obter outras informações? Então confira os Ações OTC, Ações da NASDAQ, Ações da NYSE, Ações LONES, Ações de FRA, Ações ETR, Ações da APE, Ações TSX ou Ações Amex. Procurando informações mais detalhadas como Ações de 5g, ações biotecnológicas, estoques de ouro e outras informações de nosso reportlab.
How can you buy Incyte stock on the internet?
You can easily buy Incyte stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Outra opção é usar um corretor regulamentado como Mercados de IC ou Corretores Interativos. You can an account with these brokers and start buying or trading NASDAQ:INCY stocks in a safe and complete environment to trade in.
Where to buy Incyte stock?
You will first want to find a licensed broker that supports NASDAQ:INCY stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:INCY stocks in a safe and complete environment.
Is NASDAQ:INCY stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:INCY stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Incyte stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:INCY is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Incyte stock.
How do you trade Incyte stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Incyte stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:INCY stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Incyte stock?
To sell your NASDAQ:INCY stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Incyte stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:INCY stock.
Stephen sabe muito sobre produtos financeiros e, em particular, tem uma grande paixão pelas bolsas de valores e por seus participantes. Esperamos que a informação fornecida ajude o senhor. Algo não está muito claro? Queira deixar suas perguntas ou comentários no final da página.
| Nossa pontuação ★★★★★ | |
| Nossa pontuação ★★★★★ | |
| Nossa pontuação ★★★★★ |
Boletim informativo
Notícias recentes
| |
Nossa pontuação |
0% comissão |
Ações em tempo real e dados criptográficos
Notificações, Dicas e Notícias
Melhores Ações e Guias Criptográficos
Corretor Online & Câmbio de Revisões
Reportlab Finanças é puramente um website informativo e em nenhum caso implica aconselhamento sobre investimentos. Todos os investimentos comportam riscos e o senhor pode perder todos os seus investimentos. Não invista dinheiro que o senhor não pode perder.
Reportlab Finanças
38 Holburn Lane
Heckfield Green
IP21 0UB
Reino Unido
Copyright © 2022 Reportlab.Finance | Todos os direitos reservados.
